Moeen Ali credited England white-ball captain Eoin Morgan for helping him end a run of low scores after he returned to form during the third Twenty20 international against Pakistan at Old Trafford on Tuesday.
Moeen had made a mere 10 runs in four previous international innings this season, but his dashing 61 off just 33 balls, including four fours and as many sixes, helped England recover from 69-4 as they chased a target of 191.
But Pakistan, who saw veteran Mohammad Hafeez (86 not out) and teenage debutant Haider Ali (54) share a partnership of exactly 100, won a last-ball thriller by five runs to square a three-match series at 1-1, with one no result, in the final fixture of their tour of England.
One consolation for Moeen, however, was that Tuesday's innings represented his highest score in any form of international cricket since September 2017, when he made a century against the West Indies in a 50-over match at Bristol, southwest England.
Moeen told reporters after Tuesday's close he felt he "let the team down" during his run drought and thanked Morgan, England's World Cup-winning skipper, for his support.
"A lot of credit should go to Eoin Morgan," Moeen said. "He's given me the responsibility in terms of being the vice-captain and doing team talks here and there. To get that backing from the captain... it's one of the reasons he's the best captain I've had."
- 'Feel quite special' -
Worcestershire all-rounder Moeen, who bowled Fakhar Zaman with his first-ball of off-spin on Tuesday, added of Morgan: "He gives me a lot of confidence. I haven't played well for a good period of time now and for my captain to think highly of me, for me that means a lot.
"He came up to me and said 'Would you like to give the team-talk?' It makes me feel responsible and a big part of the team. I have to back what I say as well, so I can't give the boys inspiration if I can't do it myself. It makes me feel me quite special among the boys and a big part of this team."
Moeen, asked what lay behind his run drought, said he had paid too much attention to "outside noise", although he accepted he had to take criticism "on the chin".
"I know it's only one game and I'm not going to get too far ahead, but I won't read what you guys (the press) write or what everyone else writes in general."
Moeen, who made his international debut in 2014, said he had needed to be like the "enthusiastic kid I was" when he first played for England.
"I've got to enjoy playing for England, it's a special team to be part of."
Meanwhile Moeen said he was ready to add his tally of 60 Test caps after ending his exile from red-ball international cricket earlier this year, although he accepted the likes of Dom Bess, Jack Leach and even Adil Rashid were ahead of him in the queue for a spinner's spot in Joe Root's side.
"It's a big winter so if I'm picked (for the Test team), I would play, that's for sure. If I get picked then brilliant, but if not then there's still a lot of cricket to be played."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.